SK Bioscience seeks approval for its SKY Covione COVID vaccine in Europe

| Health

Become a contributor

Bookmark Econotimes

| Health

Coinbase Enables Money Transfers via Telegram, WhatsApp, TikTok Links

Every state is about to dole out federal funding for broadband internet – not every state is ready for the task

We could make most Australians richer and still save billions – it’s not too late to fix the Stage 3 tax cuts

GSK's Pulled Myeloma Drug Outperforms J&J's Darzalex in Key Trial

ATP and Lacoste Renew Partnership, Uniting Tennis and Fashion for 2024-2026

Taking The Crypto Plunge? Why You Should Steer Clear of Unlicensed Crypto Firms

IBM Unveils Hyper Protect OSO for Enhanced Digital Asset Cold Storage Security

Public health errors: Why it's crucial to understand what they are before assessing COVID-19 responses

How does Australia's health system stack up internationally? Not bad, if you're willing to wait for it

Starbucks Faces $12 Billion Plunge Amid Longest Sales Slump in 31 Years

What the UK government's back to work plan covers – and why it is unlikely to boost people's job prospects

GTA 6: Grand Theft Auto VI Leak Forced Rockstar Games to Release Trailer Early

The potential of psychedelics to heal our racial traumas

YG Entertainment’s Shares Soared as BLACKPINK Members Renew Their Contracts

Coca-Cola Halts Cinnamon Flavor, Reflecting Strategy Shift and Consumer Trends

Twitch to Exit South Korea in 2024 Amid High Costs and Video Quality Issues

Shareholder activists can inadvertently raise CEO pay

©Econometrics LLC . All Rights Reserved.

SK Bioscience seeks approval for its SKY Covione COVID vaccine in Europe

SKY Covione

Wednesday, August 3, 2022 11:23 AM UTC

SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).

SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.

The Bill & Melinda Gates Foundation provided funding for the product development.

According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.

Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.

The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.

Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.

According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

Nvidia Adapts to US Chip Export Limits, Delays China AI Chip Launch

IBM Unveils Hyper Protect OSO for Enhanced Digital Asset Cold Storage Security

WeMade to Set Up WEMIX Play Center in Dubai via Partnership with DIFC

FxWirePro- Top altcoins for the day (Strength index) (HNTUSD)

Warfare ruins the environment – and not just on the front lines

FxWirePro:EUR/NZD downside pressure builds, key support level in focus

FxWirePro-Major pair levels and bias summary

FxWirePro: EUR/AUD key support held early, but negative factors build

Naver's CHZZK Targets Gaming Streaming Dominance, Twitch Exit Boosts Competition with YouTube, AfreecaTV

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Editor's Picks

Welcome to EconoTimes